Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


May 26, 2010 26 May, 2010

Appointment Of Stephen Nagler To The Sernova Business Advisory Board


Source: Sernova Corp.

Wednesday, May 26, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - May 26, 2010) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, is pleased to announce the appointment of Mr. Stephen Nagler, LLB to the Corporation's Business Advisory Board.

Mr. Nagler is Partner (Business and Finance International), Eaton Van Winkle LLC, New York. Mr. Nagler is a venture partner in Frontier Ventures, an emerging venture capital fund focused on Canadian life science companies and Chair of Tristate Ventures LLC, a leading New York City based angel investor group focused on investments in microcap companies, mostly in the healthcare sector, which he founded in 1999. Mr. Nagler is on the Advisory Board of BioContact and Chair of the International Finance program. Mr. Nagler is a graduate of the City College of New York and NYU Law School.

Dr. Philip Toleikis, President and CEO said "I am pleased to welcome Stephen to the Sernova team. He has been instrumental in assisting his numerous corporate clients to access capital through his extensive network of investment bankers, venture capitalists, and private equity groups. He has assisted his clients to raise more than $250 million in financings over the past four years and his wealth of international finance experience will be of significant benefit to the company as we progress toward our goal of becoming an internationally recognized clinical- stage product development organization."

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.